These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23079158)

  • 1. Treat-to-target in vasculitis: is this a sensible approach?
    Luqmani RA
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S149-53. PubMed ID: 23079158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment with rituximab for a patient with p-ANCA glomerulonephritis, alveolar bleeding and multiple relapses during haemodialysis].
    Azancot MA; Agraz Pamplona I; Fort Ros J; Marín Valencia A; Gil Carballeira I; Camps Domenech J
    Nefrologia; 2010; 30(6):710-2. PubMed ID: 21113230
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
    Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
    Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the management of systemic vasculitis: what did we learn in 2009?
    Hellmich B
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):98-103. PubMed ID: 20412713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic vasculitides: novel nomenclature and novel therapeutic approaches].
    Allali D; Chizzolini C
    Rev Med Suisse; 2014 Apr; 10(426):854-8. PubMed ID: 24834643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for ANCA-associated vasculitides.
    Guillevin L
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is 18F-FDG PET a 'potentially hazardous' or an effective tool in evaluating patients with large-vessel vasculitis?
    Treglia G; Versari A; Giovanella L; Pipitone N; Salvarani C
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S93. PubMed ID: 23380155
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 11. Refractory vasculitis.
    Rutgers A; Kallenberg CG
    Autoimmun Rev; 2011 Sep; 10(11):702-6. PubMed ID: 21600312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal disease in ANCA-associated vasculitis].
    Fumeaux D; de Seigneux S; Chizzolini C; Martin PY
    Rev Med Suisse; 2014 Feb; 10(419):493-7. PubMed ID: 24665659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
    Rich EN; Brown KK
    Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulomatosis with polyangiitis presenting as a renal mass successfully treated with rituximab.
    Lo Gullo A; Bajocchi G; Cassone G; Cavazza A; Zanichelli M; Salvarani C
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S138. PubMed ID: 24021545
    [No Abstract]   [Full Text] [Related]  

  • 19. Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
    Kallenberg CG
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii62-5. PubMed ID: 23253917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.